{
    "root": "28a9db22-f8ad-49f7-ba71-f80cb41ccf49",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Depakote",
        "suffix": {
            "text": "Sprinkles"
        }
    },
    "value": "20250501",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        }
    ],
    "indications": "Depakote Sprinkle Capsules are an anti-epileptic drug indicated for: Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 )",
    "contraindications": "Depakote Sprinkle Capsules may be swallowed whole or the contents may be sprinkled on soft food. The drug/food mixture should be swallowed immediately (avoid chewing) ( 2.2 ) Safety of doses above 60 mg/kg/day is not established ( 2.1 , 2.2 ) Complex Partial Seizures: Start at 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response; if response is not satisfactory, check valproate plasma level; see full prescribing information for conversion to monotherapy ( 2.1 ) Absence Seizures: Start at 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day until seizure control or limiting side effects ( 2.1 )",
    "warningsAndPrecautions": "Depakote Sprinkle Capsules (divalproex sodium delayed release capsules), for oral use 125 mg, are white opaque and blue, and are supplied in bottles of 100 (NDC 0074-6114-13) and Unit Dose Packages of 100 (NDC 0074-6114-11). \n                  Recommended Storage: Store capsules below 77°F (25°C).",
    "adverseReactions": "Depakote Sprinkle Capsules is contraindicated in patients: \n                  • with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions\n                      \n                     (\n                     \n                        5.1\n                     \n                     )\n                     ].\n                  • known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions \n                     (\n                     \n                        5.1\n                     \n                     )\n                     ]. \n                  \n                     • with known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid. Reactions have included multiorgan hypersensitivity, serious dermatologic reactions, and angioedema [see Warnings and Precautions \n                        (\n                        \n                           5.12\n                        \n                        , \n                        \n                           5.13\n                        \n                        , \n                           5.14\n                        \n                        )\n                        ]. \n                  \n                  • with known urea cycle disorders [see Warnings and Precautions \n                     (\n                     \n                        5.6\n                     \n                     )\n                     ]. \n                  • being treated for prophylaxis of migraine headaches: who are pregnant or in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (\n                     \n                        5.2\n                     \n                     , \n                     \n                        5.3\n                     \n                     , \n                     \n                        5.4\n                     \n                     ) and Use in Specific Populations (\n                     \n                        8.1\n                     \n                     )]."
}